Mymetics Corporation (MYMX)
Sector: Biotechnology
Industry: Biotechnology
Mymetics Corporation
| Date | Open | High | Low | Close | Volume |
|---|---|---|---|---|---|
| Nov 13, 2026 | 0.0003 | 0.0003 | 0.0003 | 0.0003 | 100 |
| Nov 12, 2026 | 0.0003 | 0.0003 | 0.0003 | 0.0003 | 100 |
| Nov 11, 2026 | 0.0003 | 0.0003 | 0.0003 | 0.0003 | 100 |
| Nov 10, 2026 | 0.0003 | 0.0003 | 0.0003 | 0.0003 | 100 |
| Nov 9, 2026 | 0.0003 | 0.0003 | 0.0003 | 0.0003 | 100 |
| Nov 6, 2026 | 0.0003 | 0.0003 | 0.0003 | 0.0003 | 100 |
| Nov 5, 2026 | 0.0003 | 0.0003 | 0.0003 | 0.0003 | 100 |
| Nov 4, 2026 | 0.0003 | 0.0003 | 0.0003 | 0.0003 | 100 |
| Nov 3, 2026 | 0.0003 | 0.0003 | 0.0003 | 0.0003 | 100 |
| Nov 2, 2026 | 0.0003 | 0.0003 | 0.0003 | 0.0003 | 100 |
| Oct 30, 2026 | 0.0003 | 0.0003 | 0.0003 | 0.0003 | 100 |
| Oct 29, 2026 | 0.0003 | 0.0003 | 0.0003 | 0.0003 | 100 |
| Oct 28, 2026 | 0.0003 | 0.0003 | 0.0003 | 0.0003 | 100 |
| Oct 27, 2026 | 0.0003 | 0.0003 | 0.0003 | 0.0003 | 100 |
| Oct 26, 2026 | 0.0003 | 0.0003 | 0.0003 | 0.0003 | 100 |
| Oct 23, 2026 | 0.0003 | 0.0003 | 0.0003 | 0.0003 | 100 |
| Oct 22, 2026 | 0.0003 | 0.0003 | 0.0003 | 0.0003 | 100 |
| Oct 21, 2026 | 0.0003 | 0.0003 | 0.0003 | 0.0003 | 100 |
| Oct 20, 2026 | 0.0003 | 0.0003 | 0.0003 | 0.0003 | 100 |
| Oct 19, 2026 | 0.0003 | 0.0003 | 0.0003 | 0.0003 | 100 |
Mymetics Corporation is a Swiss biotechnology company dedicated to the research and development of vaccines aimed at preventing infectious and debilitating diseases.
Its robust pipeline features several promising vaccine candidates, including those for HIV-1/AIDS, COVID-19, intranasal influenza, respiratory syncytial virus (RSV), malaria, and chikungunya.
The company actively collaborates with leading institutions such as the Texas Biomedical Research Institute, the PATH Malaria Vaccine Initiative, and the National Institute of Allergy and Infectious Diseases' Laboratory of Malaria Immunology and Vaccinology, focusing on the development and production of virosome-based vaccine formulations for a malaria transmission-blocking agent.
Additionally, Mymetics works with Sanofi Pasteur Biologics, LLC to assess the immunogenicity of influenza vaccines. Founded in 1990, the company was formerly known as ICHOR Corporation, adopting its current name in July 2001, and maintains its base of operations in Epalinges, Switzerland.
based on 153,333 shares outstanding
30d Avg
--
60d Avg
--
90d Avg
--